LONDON: Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the launch of its new provider access portal, myIntelX, which will provide nationwide online access for physicians to order KidneyIntelX bioprognostic testing for more accurate identification of patients at greatest risk for rapid progression of kidney disease in type 2 diabetes patients.
The Renalytix myIntelX portal is being launched in conjunction with the launch of KidneyIntelX testing within Atrium Health, which previously announced a collaboration with Renalytix in May 2021. Providers nationally can access myIntelX at https://myIntelX.com.
The myIntelX portal can streamline ordering and reporting for current testing locations across the country, including CDPHP health plans in New York State and testing in the Veterans Health Administration (VHA) in Florida (VISN 8). As part of the regional and VHA expansion for KidneyIntelX, testing is currently live in Mount Sinai Health System in New York and Wake Forest in North Carolina, and is expected to be implemented within St. Joseph’s in New York, Singing River Health System in Mississippi, University of Utah in Utah and several additional VHA centers across the country before the end of June 2022.
“Virtual capability provided through our myIntelX portal is an important step towards expanding access nationally to the KidneyIntelX proprietary technology,” said Tom McLain, President, Renalytix. “myIntelX now makes simple, early-stage risk assessment available online for practices that might not otherwise have access to KidneyIntelX integrated ordering through our large-scale health system partnerships.”
“There are over 37 million Americans with chronic kidney disease, which can be largely treatable or event preventable, but only when identified and intervened within its early stages,” said Michael J. Donovan, PhD, MD, Chief Medical Officer at Renalytix. “The quality of primary care for patients with chronic kidney disease is impacted by patient volume, co-morbidities, geography, and socioeconomic disparities. Providing a mechanism that facilitates patient identification, access and monitoring is the first step towards improving overall care.”
The launch version of the myIntelX portal supports the secure and efficient execution of both test ordering and report delivery of KidneyIntelX. The portal has been designed for scalability using cutting edge platform technology for optimal user experience. Additional features to support provider and patient education and engagement will follow as part of providing the comprehensive, fully integrated KidneyIntelX platform. After a provider registers with myIntelX online, Renalytix will enable training and support through its commercial salesforce and client service professionals to implement and sustain KidneyIntelX testing in independent practices. Renalytix will continue to process all tests through its clinical laboratories, which are built to the most rigorous standards: CLIA certified, ISO certified, CAP accredited and U.S. Food and Drug Administration (FDA) compliant.
KidneyIntelX is the only kidney health platform that has received Breakthrough Device Designation from the FDA. KidneyIntelX has secured provider agreements with more than 30 state Medicaid programs and is also covered under various commercial insurance programs.